生物制剂更早启用对重度哮喘临床缓解及结局的影响:全球真实世界队列研究
该研究基于国际重度哮喘注册库、美国CHRONICLE注册库和英国Optimum Patient Care研究数据库(26国数据),分析9241例重度哮喘患者。结果显示,生物制剂启用时间越晚,临床缓解、哮喘控制、肺功能改善及减少急性发作的可能性越低。提示对重度哮喘应更早启用生物制剂。
要点
- 生物制剂启用越早,重度哮喘患者临床缓解可能性越高。
- 哮喘病程每增加10年,生物制剂启用后12个月临床缓解的OR为0.86(0.84-0.88)。
- 潜在重度哮喘病程每增加10年,启用后急性发作率增高1.08倍(1.03-1.13)。
核心结论
- 重度哮喘患者更早启用生物制剂与更好的临床结局相关,包括临床缓解、哮喘控制、肺功能改善和减少急性发作。
- 研究提示哮喘管理应从「保留」策略转向「保护」策略,即不将生物制剂保留至重度哮喘病程较长者,而应更早启用。
研究设计与样本
- 队列研究,使用国际重度哮喘注册库、美国CHRONICLE注册库和英国Optimum Patient Care研究数据库,共26国数据。
- 关联分析纳入9241例患者。
- 采用多个代理指标描述生物制剂启用时间,包括哮喘病程、潜在重度哮喘病程、肺功能损害和频繁急性发作(均在生物制剂启用前)。
主要发现
- 生物制剂启用后12个月达到临床缓解的 odds 随启用时间延长而降低:哮喘病程每10年 OR 0.86(0.84-0.88),潜在重度哮喘病程 OR 0.78(0.63-0.96),肺功能损害 OR 0.24(0.21-0.28),每10g终生累积OCS剂量 OR 0.54(0.30-0.98)。
- 潜在重度哮喘病程每10年,生物制剂启用后急性发作率增高1.08倍(1.03-1.13),肺功能改善减少2.35%(-3.18%至-1.51%),哮喘良好控制或部分控制的 odds 降低12%(OR 0.88 [0.53-1.47])。
临床怎么用
- 对重度哮喘患者,考虑更早启用生物制剂而非延迟至标准治疗长期失败后。
- 评估生物制剂启用时机时,应关注哮喘病程、潜在重度哮喘病程、肺功能损害程度和累积OCS剂量。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Biologics generally are reserved for severe asthma (SA) after standard treatments have failed. Their recommendation is based on randomized controlled trials, designed to assess efficacy but not the optimal timing for biologic initiation. RESEARCH QUESTION: Does the timing of biologic initiation affect SA outcomes, including remission? STUDY DESIGN AND METHODS: This was a cohort study using data from the International Severe Asthma Registry, the CHRONICLE registry from the United States, and the UK Optimum Patient Care Research Database, together constituting data from 26 countries. The duration to biologic initiation was described using several proxies (eg, duration of asthma, potential SA [PSA], lung function impairment, and frequent exacerbations, all before biologic administration). The associations between these proxies and clinical remission, exacerbations, asthma control, lung function, and oral corticosteroid (OCS) use were assessed. RESULTS: The association analyses included 9,241 patients. Overall, the likelihood of achieving improvement in each outcome after biologic administration decreased with increasing time to biologic initiation. The odds of achieving clinical remission 12 months after biologic initiation were reduced for every 10 years patients had asthma before biologic initiation (0.86 [0.84-0.88], PSA (0.78 [0.63-0.96]), and had lung function impairment (0.24 [0.21-0.28]) and for every 10-g lifetime cumulative OCS dose (0.54 [0.30-0.98]). For every 10 years patients had PSA before biologic initiation, exacerbation rates after biologic initiation were 1.08 (1.03-1.13) times higher, lung function improvement was 2.35% (-3.18% to -1.51%) less, and the odds of having well-controlled or partly controlled asthma were 12% lower (0.88 [0.53-1.47]). INTERPRETATION: Our results show that earlier initiation of biologics in individuals with SA is associated with better clinical outcomes, suggesting the need to modify approaches to asthma management from a reserve to a preserve approach, that is, not reserving biologics for those with long-standing SA, and instead preserving patient lung function and possibly increasing the likelihood of better clinical outcomes with earlier biologic initiation. CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov; No.: NCT03373045; URL: www. CLINICALTRIALS: gov.
引用
- Canonica GW, Christoff GC, Tsai MJ, et al. Assessing the Impact of Earlier Initiation of Biologics on Clinical Remission and Other Outcomes in a Global Real-Life Severe Asthma Cohort From CHRONICLE, the International Severe Asthma Registry, and the Optimum Patient Care Research Database. Chest. 2026. PMID: 42716466. doi:10.1016/j.chest.2026.06.076
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。